Journal ArticleDOI
Microbial natural products: molecular blueprints for antitumor drugs
Reads0
Chats0
TLDR
This review describes only a handful of exemplary natural products and their derivatives as well as those that have served as elegant blueprints for the development of novel synthetic structures that are either currently in use or in clinical or preclinical trials together with some of their earlier analogs in some cases whose failure to proceed aided in the derivation of later compounds.Abstract:
Microbes from two of the three domains of life, the Prokarya, and Eukarya, continue to serve as rich sources of structurally complex chemical scaffolds that have proven to be essential for the development of anticancer therapeutics. This review describes only a handful of exemplary natural products and their derivatives as well as those that have served as elegant blueprints for the development of novel synthetic structures that are either currently in use or in clinical or preclinical trials together with some of their earlier analogs in some cases whose failure to proceed aided in the derivation of later compounds. In every case, a microbe has been either identified as the producer of secondary metabolites or speculated to be involved in the production via symbiotic associations. Finally, rapidly evolving next-generation sequencing technologies have led to the increasing availability of microbial genomes. Relevant examples of genome mining and genetic manipulation are discussed, demonstrating that we have only barely scratched the surface with regards to harnessing the potential of microbes as sources of new pharmaceutical leads/agents or biological probes.read more
Citations
More filters
Journal ArticleDOI
Evaluation of in vitro cytotoxic activity of different solvent extracts of Clerodendrum thomsoniae Balf.f and its active fractions on different cancer cell lines
TL;DR: In this article, the authors evaluated the cytotoxic effect of different solvents and their most active fractions of Clerodendrum thomsoniae Balf in different human cancer cell lines.
Patent
Oxanorbornadiene derivatives and their anticancer activities
Zhaoxiang Bian,Chengyuan Lin,Baomin Fan,Huaixue Mu,Yongyun Zhou,Weimin Zeng,Aiping Lu,Albert S. C. Chan +7 more
TL;DR: In this paper, a transition metal-catalyzed alkynylation of oxanorbornadiene derivatives and their antitumor effects is described. And the present invention relates to chemical entities originated from natural sources and further synthesized for therapeutic uses.
Book ChapterDOI
Bioprospecting potential of microbes for the therapeutic application
Chetan Aware,Jyoti M. Jadhav +1 more
TL;DR: In this paper , the authors discuss the bioprospecting of various bioactive compounds, their strategies of synthesis, and industrial scaling-up with future drug development challenges, and elucidate the biopharma strategies of synthesizing these compounds.
Toxicity studies of natural product in vero cells using impedance monitoring
Taufik Hakim Hamdan,Ahmad Fairuzabadi Mohd Mansor,Phirdaous Abbas,Anis Nurashikin Nordin,Yumi Zuhanis Has-Yun Hashim +4 more
TL;DR: It was found that compared to Taxol, natural products have a very low toxicant values.
Designer microbes: A promising venture
P Kirthika,Aditya Agarwal,Pradeep Chawan,Soya Rungsung,Deepshika Deuri,Shafiya Imtiaz Rafiqi,Rajni Chaudhary +6 more
TL;DR: With the incorporation of a technique called multivariate-modular pathway engineering approach”, production of anticancer taxol precursors in E. coli has been optimized.
References
More filters
Journal ArticleDOI
Natural Products as Sources of New Drugs over the Last 25 Years
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This review is an updated and expanded version of two prior reviews that were published in this journal in 1997 and 2003 and is able to identify only one de novo combinatorial compound approved as a drug in this 25 plus year time frame.
Journal ArticleDOI
Next-generation DNA sequencing.
Jay Shendure,Hanlee P. Ji +1 more
TL;DR: Next-generation DNA sequencing has the potential to dramatically accelerate biological and biomedical research, by enabling the comprehensive analysis of genomes, transcriptomes and interactomes to become inexpensive, routine and widespread, rather than requiring significant production-scale efforts.
Journal ArticleDOI
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This review is an updated and expanded version of the three prior reviews and adds a new designation, "natural product botanical" or "NB", to cover those botanical "defined mixtures" that have now been recognized as drug entities by the FDA and similar organizations.
Journal ArticleDOI
Natural Products as Sources of New Drugs over the Period 1981−2002
TL;DR: From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well, and in the area of cancer, the percentage of small molecule, new chemical entities that are nonsynthetic has remained at 62% averaged over the whole time frame.
Journal ArticleDOI
Histone deacetylases (HDACs): characterization of the classical HDAC family
Annemieke J.M. de Ruijter,Albert H. van Gennip,Huib N. Caron,Stephan Kemp,André B.P. van Kuilenburg +4 more
TL;DR: In this paper, a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity is presented.
Related Papers (5)
Natural Products as Sources of New Drugs over the Last 25 Years
David J. Newman,Gordon M. Cragg +1 more
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
David J. Newman,Gordon M. Cragg +1 more